Should I buy or sell Geron stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks .

What is Geron's stock price target for 2024?

3 brokers have issued 12 month price objectives for Geron's shares. Their GERN share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 146.1% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts .

How have GERN shares performed in 2023?

Geron's stock was trading at $2.42 at the beginning of 2023. Since then, GERN shares have decreased by 20.2% and is now trading at $1.93. View the best growth stocks for 2023 here .

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our GERN earnings forecast .

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.14 million. Geron had a negative net margin of 55,138.49% and a negative trailing twelve-month return on equity of 70.26%.

What ETFs hold Geron's stock?

ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , WisdomTree BioRevolution Fund (WDNA) , Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com . John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX) , Dynavax Technologies (DVAX) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Rigel Pharmaceuticals (RIGL) , Chesapeake Energy (CHKAQ) , Organigram (OGI) , SCYNEXIS (SCYX) and Bionano Genomics (BNGO) .

Who are Geron's major shareholders?

Geron's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (8.51%), MPM Bioimpact LLC (1.97%), Wellington Management Group LLP (1.92%), FMR LLC (1.39%), Northern Trust Corp (0.99%) and Invesco Ltd. (0.84%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends .

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Geron (GERN) Stock Price, News & Analysis

$1.93

-0.14 (-6.76%)

(As of 04:00 PM ET)

Compare

Today's Range: $1.88
▼
$2.07
50-Day Range: $1.74
▼
$2.09
52-Week Range: $1.68
▼
$3.84

Volume: 4.90 million shs
Average Volume: 6.54 million shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.75

Geron MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 146.1% Upside
$4.75 Price Target
Short Interest: Bearish
8.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -3.05
Upright™ Environmental Score
News Sentiment: 0.72
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.35) to ($0.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

485th out of 945 stocks

Pharmaceutical Preparations Industry

216th out of 436 stocks

3.5

Analyst's Opinion

Consensus Rating
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.75, Geron has a forecasted upside of 146.1% from its current price of $1.93.
Amount of Analyst Coverage
Geron has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.19% of the outstanding shares of Geron have been sold short.
Short Interest Ratio / Days to Cover
Geron has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Geron has recently decreased by 1.42%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Geron does not currently pay a dividend.
Dividend Growth
Geron does not have a long track record of dividend growth.

1.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Geron has received a -20.15% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Geron is -3.05.

3.7

News and Social Media Coverage

News Sentiment
Geron has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Geron this week, compared to 3 articles on an average week.
Search Interest
13 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.
MarketBeat Follows
2 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Geron insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.10% of the stock of Geron is held by insiders.
Percentage Held by Institutions
65.44% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Geron is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Geron is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Geron has a P/B Ratio of 9.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GERN Stock News Headlines

December 11, 2023 | finance.yahoo.com

Recent uptick might appease Geron Corporation (NASDAQ:GERN) institutional owners after losing 13% over the past year

December 6, 2023 | finance.yahoo.com

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

December 11, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 4, 2023 | msn.com

Geron shares rise after positive trial results of blood disorder candidate

December 4, 2023 | seekingalpha.com

Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case

December 4, 2023 | finance.yahoo.com

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

November 29, 2023 | bizjournals.com

Peninsula biotech looks to hire 50-60 reps in anticipation of first drug approval

November 28, 2023 | finance.yahoo.com

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

December 11, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 21, 2023 | thestreet.com

Geron (GERN) Stock Surges After FDA Removes Full Clinical Hold on Imetelstat Application

November 7, 2023 | finance.yahoo.com

Geron to Participate at Upcoming Investor Conferences in November

November 3, 2023 | markets.businessinsider.com

Geron’s Growth Prospects: Expanding Commercial Team, Imetelstat Development, and Financial Stability

November 3, 2023 | finance.yahoo.com

Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call Transcript

November 2, 2023 | fool.com

Geron (GERN) Q3 2023 Earnings Call Transcript

November 2, 2023 | seekingalpha.com

Geron Corporation 2023 Q3 - Results - Earnings Call Presentation

November 2, 2023 | markets.businessinsider.com

Geron Corporation Q3 Loss beats estimates

November 2, 2023 | finance.yahoo.com

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

November 2, 2023 | finance.yahoo.com

Geron Corp (GERN) Reports Q3 2023 Financial Results and Business Highlights

November 1, 2023 | benzinga.com

4GERN : Geron Earnings Preview

October 31, 2023 | finance.yahoo.com

Techne (TECH) Q1 Earnings and Revenues Miss Estimates

October 26, 2023 | finance.yahoo.com

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

October 23, 2023 | seekingalpha.com

Geron Corporation Stock: Another Buying Opportunity

September 29, 2023 | markets.businessinsider.com

Geron Reports EMA Validation Of Marketing Authorization Application For Imetelstat

September 29, 2023 | finance.yahoo.com

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

September 13, 2023 | msn.com

Goldman Sachs Upgrades Geron (GERN)

September 12, 2023 | msn.com

Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs

See More Headlines

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:GERN
CUSIP: 37416310
CIK: 886744
Web: www.geron.com
Phone: (650) 473-7700
Fax: 650-473-7750
Employees: 107
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.75
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +144.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-141,900,000.00
Net Margins: -55,138.49%
Pretax Margin: -55,138.49%
Return on Equity: -70.26%
Return on Assets: -48.43%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 3.75
Quick Ratio: 3.75

Sales & Book Value

Annual Sales: $600,000.00
Price / Sales: 1,755.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 9.70

Miscellaneous

Outstanding Shares: 543,060,000
Free Float: 526,229,000
Market Cap: $1.05 billion
Optionable: Optionable
Beta: 0.79

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. John A. Scarlett M.D. (Age 72)
Chairman of the Board, President & CEO
Comp: $1.53M
Dr. Andrew J. Grethlein (Age 59)
Executive VP & COO
Comp: $847.2k
Ms. Michelle J. Robertson (Age 56)
Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Ms. Aron Feingold
Vice President of Investor Relations & Corporate Communications
Mr. Scott Samuels
Executive VP, Chief Legal Officer & Corporate Secretary
Ms. Shannon Odam
Vice President of Human Resources
Ms. Melissa A. Kelly Behrs (Age 59)
Executive VP of Business Operations & Chief Alliance Officer
Comp: $753.22k
Mr. Anil Kapur (Age 53)
Executive VP of Corporate Strategy & Chief Commercial Officer
Comp: $654.89k
Mr. Edward E. Koval (Age 61)
Executive VP & Chief Business Officer
Dr. Faye Feller M.D. (Age 41)
Executive VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.
What is Geron's stock price target for 2024?: 3 brokers have issued 12 month price objectives for Geron's shares. Their GERN share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 146.1% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.
How have GERN shares performed in 2023?: Geron's stock was trading at $2.42 at the beginning of 2023. Since then, GERN shares have decreased by 20.2% and is now trading at $1.93.
View the best growth stocks for 2023 here.
When is Geron's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our GERN earnings forecast.
How were Geron's earnings last quarter?: Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.14 million. Geron had a negative net margin of 55,138.49% and a negative trailing twelve-month return on equity of 70.26%.
What ETFs hold Geron's stock?: ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), WisdomTree BioRevolution Fund (WDNA), Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is John A. Scarlett's approval rating as Geron's CEO?: 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Geron own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).
Who are Geron's major shareholders?: Geron's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (8.51%), MPM Bioimpact LLC (1.97%), Wellington Management Group LLP (1.92%), FMR LLC (1.39%), Northern Trust Corp (0.99%) and Invesco Ltd. (0.84%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends.
How do I buy shares of Geron?: Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Geron (GERN) Stock Price, News & Analysis

Geron MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Geron Stock (NASDAQ:GERN)

GERN Stock Price History

GERN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GERN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™